share_log

bluebird bio | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(8.0%)

SEC ·  Oct 23, 2024 03:30

Summary by Moomoo AI

On September 30, 2024, BlackRock, Inc., a Delaware-based investment management corporation, filed a Schedule 13G with the Securities and Exchange Commission (SEC), disclosing an 8.0% ownership stake in bluebird bio, a biotechnology company. The filing indicates that BlackRock has sole dispositive power over 15,443,767 shares of bluebird bio's common stock. This stake does not grant BlackRock any sole voting power, as indicated in the filing. The Schedule 13G is a regulatory filing that is required when a party acquires more than 5% of a company's stock and is used to declare the acquisition and ownership status of the filer. The filing was certified by Spencer Fleming, Attorney-In-Fact for BlackRock, Inc., and was dated October 22, 2024.
On September 30, 2024, BlackRock, Inc., a Delaware-based investment management corporation, filed a Schedule 13G with the Securities and Exchange Commission (SEC), disclosing an 8.0% ownership stake in bluebird bio, a biotechnology company. The filing indicates that BlackRock has sole dispositive power over 15,443,767 shares of bluebird bio's common stock. This stake does not grant BlackRock any sole voting power, as indicated in the filing. The Schedule 13G is a regulatory filing that is required when a party acquires more than 5% of a company's stock and is used to declare the acquisition and ownership status of the filer. The filing was certified by Spencer Fleming, Attorney-In-Fact for BlackRock, Inc., and was dated October 22, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Related Stocks Related Stocks
    Symbol Mini Chart Price
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    Log In for the Full List
    Reassessing Chinese Assets
    Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
    Discussing
    Many institutions are bullish! What's ahead for Chinese stocks in 2025?
    Recently, institutions such as Goldman Sachs, Morgan Stanley, and Appaloosa LP have spoken positively about Chinese assets. 🎙️Discussion: 1 Show More
    China's asset revaluation sparks debate: What are mooers buying?